Direct supply from state-of-the-art solid-phase synthesis reactors. Each commercial batch is backed by comprehensive analytical documentation, strict HPLC assay guarantees, and lot-to-lot traceability for international compliance.
The global cosmeceutical and regenerative biotechnology markets have transformed Copper Tripeptide-1 (GHK-Cu, CAS 89030-95-5) from a niche laboratory biochemical into a foundational high-volume raw material requiring multi-ton synthetic infrastructure.
Sourcing commercial copper tripeptide requires strict analytical verification beyond basic assay numbers. Unreacted copper salts cause catalytic oxidation of delicate carrier lipids in final cosmetic emulsions. Our manufacturing protocol employs specialized chelometric resin separation to lower free Cu²ᵊ below 0.1%, preventing emulsion breakdown and unwanted discolouration in downstream formulation.
While small peptide fragments can theoretically be synthesized via liquid-phase peptide synthesis (LPPS), commercial multi-kilogram production of high-purity GHK-Cu relies on optimized Solid-Phase Peptide Synthesis (SPPS) using 2-chlorotrityl chloride resin. This approach eliminates racemization at the L-histidine residue and prevents the formation of D-His diastereomers that lack physiological receptor-binding activity.
Industrial GHK-Cu pricing varies based on purity grades (cosmetic vs. medical/topical pharmaceutical), batch sizes, counter-ion specification (acetate vs. TFA-free), and documentation depth. Below is our baseline bulk manufacturing pricing tier.
| Procurement Tier | Volume (Net Weight) | Purity (RP-HPLC) | Free Cu²ᵊ Content | Counter-Ion Profile | Lead Time | Indicative Price Range |
|---|---|---|---|---|---|---|
| Pilot / R&D Evaluation | 100g – 500g | ≥ 98.0% | ≤ 0.3% | Acetate (≤ 10%) | Immediate Ex-Stock | $1.80 – $2.40 / gram |
| Commercial Batch Tier 1 | 1 kg – 5 kg | ≥ 98.5% | ≤ 0.2% | Acetate (≤ 8%) | 3 – 7 Working Days | $1,100 – $1,450 / kg |
| Industrial Scale Tier 2 | 10 kg – 25 kg | ≥ 99.0% | ≤ 0.1% | Controlled Acetate | 10 – 14 Working Days | $850 – $1,050 / kg |
| Enterprise Contract Tier 3 | 50 kg – 200+ kg | ≥ 99.2% – 99.5% | ≤ 0.05% | Customized / Ultra-Low | Scheduled Supply Agreement | $680 – $820 / kg |
| Clinical Grade / Medical Topicals | Custom Campaigns | ≥ 99.5% (EP/USP Criteria) | Undetectable Trace | TFA-Free / Pure Acetate | Validated GMP Campaign | Custom CDMO Quotation |
*Pricing reflects global ex-works terms. High-volume contract agreements are subject to raw material copper market indexing and dedicated custom synthesis schedules.
GHK (Glycyl-L-Histidyl-L-Lysine) is a human plasma-native tripeptide exhibiting an extraordinary binding affinity for copper(II) ions ($K = 10^{-16}\text{ M}$). When complexed into GHK-Cu, it serves as a powerful bioregulatory engine across three dominant application verticals.
GHK-Cu upregulates Collagen Type I, Type III, and elastin synthesis via primary dermal fibroblast stimulation. It activates metalloproteinases (MMPs) and TIMPs systematically, clearing damaged proteins and micro-scar tissue while improving skin density, firmness, and dermal architectural resilience.
In trichology, GHK-Cu inhibits dihydrotestosterone (DHT) induced perifollicular inflammation while increasing follicular unit enlargement. Clinical data demonstrates marked vascularization improvements around the dermal papilla via VEGF secretion, extending the anagen growth cycle.
Following fractional laser therapy, microneedling, or micro-focused ultrasound, topically delivered GHK-Cu significantly accelerates re-epithelialization. It dampens pro-inflammatory cascades (TNF-α, IL-6) and supports antioxidant defense through superoxide dismutase (SOD) expression.
As sustainability pressures and strict global pharmacopeial standards reshape the peptide CDMO landscape, peptide engineering transitions toward green chemistry principles and intelligent continuous processing.
Transitioning from traditional batch stirred reactors to microfluidic flow reactors allows microsecond mixing kinetics during Fmoc-deprotection and amino acid coupling. This minimizes secondary by-product generation, reduces solvent consumption by up to 45%, and guarantees perfectly homogeneous heat transfer across large-scale campaigns.
Phasing out hazardous dipolar aprotic solvents such as DMF (Dimethylformamide) and NMP (N-Methyl-2-pyrrolidone) in favor of bio-based, REACH-compliant alternatives including 2-MeTHF and Cyrene. These greener protocols ensure absolute safety compliance for European and North American enterprise buyers.
Deploying automated in-line spectrophotometric sensors to track real-time copper-ion coordination during the aqueous complexation phase. This closed-loop process achieves precise 1:1 molar stoichiometry, completely preventing excess uncoordinated copper ions and avoiding uncomplexed GHK peptide residues.
Equipping purification suites with large-diameter Dynamic Axial Compression (DAC) columns packed with modified spherical silica gel. This design allows single-pass purity runs exceeding 99.5%, efficiently eliminating closely eluting deletion peptides (Gly-His or His-Lys fragments).
Utilizing predictive thermal physics to model ice sublimation pathways within industrial freeze dryers. Tailoring freezing and drying ramp rates preserves the amorphous blue matrix of GHK-Cu, ensuring instantaneous reconstitution, extended shelf stability, and low cake hygroscopicity.
Pioneering CDMO developments linking the basic GHK-Cu framework with lipophilic carbon chains (Palmitoyl-GHK-Cu) or cell-penetrating carrier sequences to bypass stratum corneum barriers without compromising copper chelation stability.
Enterprise procurement requires reliable regulatory navigation. From European cosmetic safety assessments to US FDA drug master files, we back every product with certified documentation and validated analytics.
Our GHK-Cu carries full international INCI standardization (Copper Tripeptide-1). For brands expanding into the EU, our materials conform to REACH registration thresholds and support European CPNP notification files with complete toxicological portfolios.
Every commercial batch is accompanied by comprehensive analytical verification: RP-HPLC chromatograms for purity, ESI-MS for molecular mass confirmation ($502.5 \text{ g/mol}$ mono-isotopic), ICP-MS for total and free copper balance, residual solvents (GC-MS), and bioburden tests.
Peptide stability demands strict logistics discipline. We utilize temperature-monitored pharmaceutical cold packaging (dry ice or qualified $2\text{--}8^\circ\text{C}$ insulated phase packs) combined with expedited door-to-door global air freight across North America, Europe, Asia, and the Middle East.
Real-world technical, formulation, and commercial questions answered with engineering precision.
Our synthesis infrastructure produces complex generic APIs, GLP-1/GIP co-agonists, immunopeptides, and proprietary research sequences alongside commercial cosmetic actives.
Thin